KR20230007368A - 항-tmprss6 항체 및 이의 용도 - Google Patents
항-tmprss6 항체 및 이의 용도 Download PDFInfo
- Publication number
- KR20230007368A KR20230007368A KR1020227038805A KR20227038805A KR20230007368A KR 20230007368 A KR20230007368 A KR 20230007368A KR 1020227038805 A KR1020227038805 A KR 1020227038805A KR 20227038805 A KR20227038805 A KR 20227038805A KR 20230007368 A KR20230007368 A KR 20230007368A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- ser
- val
- leu
- tmprss6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063006695P | 2020-04-07 | 2020-04-07 | |
| US63/006,695 | 2020-04-07 | ||
| US202163158265P | 2021-03-08 | 2021-03-08 | |
| US63/158,265 | 2021-03-08 | ||
| PCT/US2021/025775 WO2021207072A1 (en) | 2020-04-07 | 2021-04-05 | Anti-tmprss6 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230007368A true KR20230007368A (ko) | 2023-01-12 |
Family
ID=75888147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227038805A Pending KR20230007368A (ko) | 2020-04-07 | 2021-04-05 | 항-tmprss6 항체 및 이의 용도 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US12215170B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4126220A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7813234B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230007368A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115243762B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021251087A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174339A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202204422A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021207072A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021251087A1 (en) | 2020-04-07 | 2022-12-01 | Mabwell Therapeutics Inc. | Anti-TMPRSS6 antibodies and uses thereof |
| US20230295345A1 (en) * | 2020-04-07 | 2023-09-21 | Mabwell Therapeutics, Inc. | Anti-tmprss6 antibodies and uses thereof |
| WO2022240877A1 (en) | 2021-05-11 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss6 antibodies and uses thereof |
| KR20250128393A (ko) * | 2022-11-25 | 2025-08-27 | 맵웰 테라퓨틱스 인크. | 항-tmprss6 항체 및 그의 용도 |
| CN120936629A (zh) * | 2023-04-04 | 2025-11-11 | 迪斯克医药公司 | 抗tmprss6抗体及其用途 |
| WO2024211900A1 (en) * | 2023-04-06 | 2024-10-10 | Memorial Sloan-Kettering Cancer Center | Il-10 receptor antibodies and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
| WO2005023835A2 (en) | 2003-09-09 | 2005-03-17 | Irm Llc | Modulators of transmembrane protease serine 6 |
| GB0614201D0 (en) | 2006-07-18 | 2006-08-23 | Univ Cardiff | Matriptase-2 |
| PE20130588A1 (es) | 2007-02-02 | 2013-05-21 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| EP2776564B1 (en) * | 2011-11-07 | 2019-10-02 | Ionis Pharmaceuticals, Inc. | Modulation of tmprss6 expression |
| AR093620A1 (es) * | 2012-12-17 | 2015-06-10 | Lilly Co Eli | Anticuerpos bmp-6 |
| CN106062004A (zh) | 2013-12-17 | 2016-10-26 | 科马布有限公司 | 人靶标 |
| WO2016071701A1 (en) * | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| AU2016302768B2 (en) * | 2015-07-31 | 2019-08-22 | Medimmune Limited | Methods for treating hepcidin-mediated disorders |
| GB201815629D0 (en) | 2018-09-25 | 2018-11-07 | Kymab Ltd | Antagonists |
| EP4065607A1 (en) | 2019-11-29 | 2022-10-05 | Kymab Limited | Treatment for physiological iron overload |
| AU2021251087A1 (en) | 2020-04-07 | 2022-12-01 | Mabwell Therapeutics Inc. | Anti-TMPRSS6 antibodies and uses thereof |
| CA3216106A1 (en) | 2021-04-26 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof |
| WO2022229150A1 (en) | 2021-04-27 | 2022-11-03 | Silence Therapeutics Gmbh | Sirna targeting tmprss6 for the treawtment of myeloproliferative disorders |
-
2021
- 2021-04-05 AU AU2021251087A patent/AU2021251087A1/en active Pending
- 2021-04-05 KR KR1020227038805A patent/KR20230007368A/ko active Pending
- 2021-04-05 WO PCT/US2021/025775 patent/WO2021207072A1/en not_active Ceased
- 2021-04-05 EP EP21724822.8A patent/EP4126220A1/en active Pending
- 2021-04-05 CA CA3174339A patent/CA3174339A1/en active Pending
- 2021-04-05 US US17/916,008 patent/US12215170B2/en active Active
- 2021-04-05 JP JP2022548950A patent/JP7813234B2/ja active Active
- 2021-04-05 CN CN202180007339.2A patent/CN115243762B/zh active Active
- 2021-04-06 TW TW110112433A patent/TW202204422A/zh unknown
-
2023
- 2023-06-05 US US18/329,172 patent/US11866513B2/en active Active
-
2025
- 2025-01-31 US US19/042,342 patent/US20250304719A1/en active Pending
-
2026
- 2026-01-29 JP JP2026013680A patent/JP2026089058A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4126220A1 (en) | 2023-02-08 |
| CN115243762B (zh) | 2026-07-28 |
| WO2021207072A1 (en) | 2021-10-14 |
| JP2026089058A (ja) | 2026-05-29 |
| CN115243762A (zh) | 2022-10-25 |
| JP7813234B2 (ja) | 2026-02-12 |
| US11866513B2 (en) | 2024-01-09 |
| CA3174339A1 (en) | 2021-10-14 |
| US20230203196A1 (en) | 2023-06-29 |
| TW202204422A (zh) | 2022-02-01 |
| AU2021251087A1 (en) | 2022-12-01 |
| JP2023520969A (ja) | 2023-05-23 |
| US12215170B2 (en) | 2025-02-04 |
| US20250304719A1 (en) | 2025-10-02 |
| US20230348623A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110214154B (zh) | 抗cd47抗体及其用途 | |
| EP2997042B1 (en) | Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications | |
| JP7813234B2 (ja) | 抗tmprss6抗体及びその用途 | |
| RU2571224C2 (ru) | Гуманизированные антитела против axl | |
| KR102933484B1 (ko) | 항-il-27 항체 및 그의 용도 | |
| KR102513989B1 (ko) | 간 질환을 치료하거나 예방하는 방법 | |
| KR20190133160A (ko) | 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자 | |
| RU2744909C2 (ru) | Способ лечения или предотвращения инсульта | |
| KR20220080015A (ko) | Alk7 결합 단백질 및 이들의 용도 | |
| KR20220016136A (ko) | Alk7 결합 단백질 및 이의 용도 | |
| US20230295345A1 (en) | Anti-tmprss6 antibodies and uses thereof | |
| HK40079278A (en) | Anti-tmprss6 antibodies and uses thereof | |
| US20250136718A1 (en) | Anti-tmprss6 antibodies and uses thereof | |
| HK40104812A (en) | Anti-tmprss6 antibodies and uses thereof | |
| CN118078985A (zh) | 抗tmprss6抗体及其用途 | |
| RU2790023C2 (ru) | Способы лечения заболевания с применением ингибиторов костного морфогенетического белка 6 (вмр6) | |
| KR20250128393A (ko) | 항-tmprss6 항체 및 그의 용도 | |
| HK40013319B (en) | Anti-cd47 antibody and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |